title: Malignant nonepithelial prostate tumors: FDG PET/CT findings with MRI and CT correlation.
abstract: OBJECTIVE
  The aim of this study was to evaluate F-FDG PET/CT findings of malignant nonepithelial prostate tumors and their correlation with MRI and CT images.
  
  
  METHODS
  FDG PET/CT findings were reviewed in 12 patients with malignant nonepithelial prostate tumor confirmed by pathology. The location, size, SUVmax, pathologic findings, and available MRI and CT images of the tumors were reviewed.
  
  
  RESULTS
  Of the 12 patients (mean age, 41 years; age range, 19-66 years), 9 had normal prostate-specific antigen levels. The mean size of the tumors was 7.1 cm in diameter ranging from 4.6 to 10.5 cm. All the tumors showed increased metabolic activity with mean SUVmax of 17.5 ranging from 3.6 to 46.8. The high-grade malignant tumors tended to show higher FDG uptake, whereas the intermediate-grade and low-grade malignant ones tended to show lower FDG uptake. Seven tumors had local invasion or distant metastases. Lung was the most common metastatic site. On MRI, the tumors showed well-circumscribed or ill-circumscribed margins with inhomogeneous enhancement. On CT, the tumors showed hypodensity with slight to moderate enhancement.
  
  
  CONCLUSIONS
  The malignant nonepithelial prostate tumors tended to have large sizes at presentation, have high FDG uptake, and affect a younger population with normal prostate-specific antigen levels. FDG PET/CT may be useful for the assessment of tumor grade and for detecting the distant metastases, whereas the MRI or enhanced CT may be more helpful for describing the relationship between the tumor and adjacent structures.
authors.affiliation: From the Departments of *Nuclear Medicine, †Radiotherapy, ‡Pathology, §Radiology, and ¶Interventional Radiology, Changhai Hospital, Second Military Medical University, Shanghai, China.
authors.forename: Aisheng
authors.initials: A
authors.lastname: Dong
authors.forename: Huojun
authors.initials: H
authors.lastname: Zhang
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.forename: Jing
authors.initials: J
authors.lastname: Gong
authors.forename: Changjing
authors.initials: C
authors.lastname: Zuo
authors.forename: Jijin
authors.initials: J
authors.lastname: Yang
authors.forename: Jianping
authors.initials: J
authors.lastname: Lu
mesh_terms: D000328:Adult; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000473:pathology; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D017430:Prostate-Specific Antigen